Marshall Richard Henry 4
4 · TriSalus Life Sciences, Inc. · Filed Jun 29, 2026
Research Summary
AI-generated summary of this filing
TriSalus (TLSI) CMO Marshall Henry Receives Stock Awards
What Happened Marshall Richard Henry, Chief Medical Officer of TriSalus Life Sciences (TLSI), received equity awards on June 29, 2026: 60,000 restricted stock units (RSUs) and 120,000 derivative awards (reported as a grant at $0.00). The filing shows acquisition values of $0 for both items because no cash was paid at grant. These are awards, not open‑market purchases or sales.
Key Details
- Transaction date: 2026-06-29; reported on Form 4 filed the same day.
- Awards: 60,000 RSUs (payable in common stock) and 120,000 derivative awards (option-style grant) at $0.00.
- Vesting for RSUs (F1): vests in four equal annual installments beginning June 29, 2027, subject to continued service.
- Vesting for derivative award (F2): 1/4 vests on June 29, 2027 (one‑year anniversary), then 1/36th of the remainder vests monthly thereafter, subject to continued service.
- Shares owned after the transaction: not reported in the provided summary of the Form 4.
- Filing timeliness: filed the same day as the transaction (no late filing indicated in this record).
Context RSUs convert to actual shares only as they vest and are typically seen as a retention incentive; the derivative award follows an option‑style vesting schedule and will require vesting (and possibly exercise) before resulting in shares. Because these are grants (not purchases or sales), they reflect compensation/retention actions rather than an immediate market‑signal buy or sell.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-29+60,000→ 90,000 total - Award
Employee Stock Option (right to buy)
[F2]2026-06-29+120,000→ 253,000 totalExercise: $4.74Exp: 2036-06-29→ Common Stock (120,000 underlying)
Footnotes (2)
- [F1]Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in four equal annual installments commencing on the one-year anniversary of the grant date of June 29, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
- [F2]One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of June 29, 2026 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.